THE RULING: India's Supreme Court rejected Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients worldwide will get continued access to cheap versions of lifesaving medicines.
THE ARGUMENT: The Swiss drugmaker had argued that it needed a patent to protect its investment in the cancer drug Glivec, while activists said the drug did not merit intellectual property protection in India because it was not a new medicine.
THE FALLOUT: In response to the ruling, Novartis said it would not invest in drug research in India.
- Pharmaceuticals & Drug Trials
- Novartis AG